Single-Institution Phase 1/2 Prospective Trial Evaluating Three-Fraction Partial Breast Irradiation: Four Year Outcomes Including Quantitative Cosmesis and Patient-Reported Outcomes

被引：0
|
作者：
Raju, S. C. [1 ]
Mahmood, M. [2 ]
Zoberi, J. E. [3 ]
Thomas, M. A. [1 ]
Ochoa, L. L. [1 ]
Garcia-Ramirez, J. L. [4 ]
Zoberi, I. [3 ]
机构：
[1] Washington Univ St Louis, St Louis, MO USA
[2] Washington Univ, Sch Med St Louis, Dept Radiat Oncol, St Louis, MO USA
[3] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA
[4] Washington Univ, Sch Med, Springfield, MO USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
238
引用
收藏
页码：S83 / S83
页数：1
相关论文
共 28 条
  • [21] Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M)
    Chounta, Vasiliki
    Overton, Edgar T.
    Mills, Anthony
    Swindells, Susan
    Benn, Paul D.
    Vanveggel, Simon
    van Solingen-Ristea, Rodica
    Wang, Yuanyuan
    Hudson, Krischan J.
    Shaefer, Mark S.
    Margolis, David A.
    Smith, Kimberly Y.
    Spreen, William R.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (06): : 849 - 862
  • [22] Impact of objective response (OR) on patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer (ABC) and a germline BRCA1/2 (gBRCA) mutation in the phase III EMBRACA trial
    Fasching, P. A.
    Quek, R. G. W.
    Bhattacharyya, H.
    Hurvitz, S. A.
    Rugo, H. S.
    Ettl, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [23] A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.
    Iwamoto, Mitsuhiko
    Kimura, Kosei
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kimura, Kosei
    Iwamoto, Mitsuhiko
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (05) : 923 - 933
  • [25] A phase II, multicenter, single-arm trial of eribulin as first- or second-line chemotherapy for HER2-negative advanced or metastatic breast cancer: evaluation of efficacy, safety, and patient-reported outcomes
    Kosei Kimura
    Mitsuhiko Iwamoto
    Satoru Tanaka
    Daigo Yamamoto
    Katsuhide Yoshidome
    Hiroyuki Ogura
    Risa Terasawa
    Nobuki Matsunami
    Yuko Takahashi
    Toshikatsu Nitta
    Takashi Morimoto
    Hiroya Fujioka
    Kanako Kawaguchi
    Kazuhisa Uchiyama
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 923 - 933
  • [26] Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
    Hurvitz, S. A.
    Quek, R. G. W.
    Turner, N. C.
    Telli, M. L.
    Rugo, H. S.
    Mailliez, A.
    Ettl, J.
    Grischke, E.
    Mina, L. A.
    Balmana, J.
    Fasching, P. A.
    Bhattacharyya, H.
    Hannah, A. L.
    Robson, M. E.
    Wardley, A. M.
    EUROPEAN JOURNAL OF CANCER, 2018, 104 : 160 - 168
  • [27] Responder analyses of patient-reported outcomes for evaluating the clinical significance of first-line S-1 over taxane therapy among patients with metastatic breast cancer: the open-label randomized phase III SELECT-BC trial
    Kawahara, Takuya
    Shimozuma, Kojiro
    Shiroiwa, Takeru
    Hagiwara, Yasuhiro
    Uemura, Yukari
    Watanabe, Takanori
    Fukuda, Takashi
    Ohashi, Yasuo
    Mukai, Hirofumi
    QUALITY OF LIFE RESEARCH, 2016, 25 : 116 - 116
  • [28] Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer
    Ganz, Patricia A.
    Bandos, Hanna
    Spanic, Tanja
    Friedman, Sue
    Mueller, Volkmar
    Kuemmel, Sherko
    Delaloge, Suzette
    Brain, Etienne
    Toi, Masakazu
    Yamauchi, Hideko
    de Duenas, Eduardo-M.
    Armstrong, Anne
    Im, Seock-Ah
    Song, Chuan-gui
    Zheng, Hong
    Sarosiek, Tomasz
    Sharma, Priyanka
    Geng, Cuizhi
    Fu, Peifen
    Rhiem, Kerstin
    Frauchiger-Heuer, Heike
    Wimberger, Pauline
    de Roodenbeke, Daphne t'Kint
    Liao, Ning
    Goodwin, Annabel
    Chakiba-Brugere, Camille
    Friedlander, Michael
    Lee, Keun Seok
    Giacchetti, Sylvie
    Takano, Toshimi
    Henao-Carrasco, Fernando
    Virani, Shamsuddin
    Valdes-Albini, Frances
    Domchek, Susan M.
    Bane, Charles
    Mccarron, Edward C.
    Mita, Monica
    Rossi, Giovanna
    Rastogi, Priya
    Fielding, Anitra
    Gelber, Richard D.
    Scheepers, Elsemieke D.
    Cameron, David
    Garber, Judy
    Geyer, Charles E.
    Tutt, Andrew N. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1288 - 1300
123